38.02 0.00 (0.00%)
After hours: 6:28PM EST
Previous close | 38.54 |
Open | 37.96 |
Bid | 37.98 x 900 |
Ask | 38.02 x 1200 |
Day's range | 37.75 - 38.15 |
52-week range | 31.43 - 48.25 |
Volume | 7,606,945 |
Avg. volume | 4,991,362 |
Market cap | 95.038B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 38.33 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.05 (5.32%) |
Ex-dividend date | 12 Nov 2020 |
1y target est | N/A |
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK). Vir and Gilead plan to work together on a phase 2 study evaluating Vir's VIR-2218 with Gilead's selgantolimod in treating individuals infected with the hepatitis B virus (HBV).
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline